Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
29 oct. 2020 16h30 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an...
Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors
07 août 2020 16h30 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...
Eidos Therapeutics Reports Second Quarter 2020 Financial Results and Business Update
06 août 2020 16h30 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the second quarter ended June 30, 2020 and provided an...
Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update
08 mai 2020 16h30 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided an...
Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update
26 févr. 2020 16h30 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and...
CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
16 nov. 2019 18h58 HE
|
Eidos Therapeutics, Inc.
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular...
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
16 nov. 2019 17h30 HE
|
Eidos Therapeutics, Inc.
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular...
Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update
31 oct. 2019 16h30 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial...
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
30 sept. 2019 07h00 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need...
Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
19 sept. 2019 08h00 HE
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on...